Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

Channick R, Medrek S, Delcroix M, Gaine S, Jansa P, Lang I, McLaughlin V, Mehta S, Pulido T, Sastry B, Souza R, Torbicki A, Zhao[...]

T cell immune senescence is associated with frailty and sarcopenia in lung transplant candidates

Schaenman JM, Pickering H, Reed EF, Rossetti M, Seligman B, Weigt SS, Shino M, Sayah D, Belperio J, Hu A, Prosper A, Ruchalski K, Ardehali[...]

“It Looks Arterial”: The Chest X-Ray of Nightmares

Chen T. "It Looks Arterial": The Chest X-Ray of Nightmares. Cureus. 2025 Feb 23;17(2):e79532. doi: 10.7759/cureus.79532. PMID: 40144411; PMCID: PMC11937719.